tiprankstipranks
Immunovant (DE:4YB)
STUTTGART:4YB
Germany Market

Immunovant (4YB) Stock Forecast & Price Target

0 Followers
See the Price Targets and Ratings of:

4YB Analyst Ratings

Strong Buy
10Ratings
Strong Buy
8 Buy
2 Hold
0 Sell
Based on 10 analysts giving stock ratings to
Immunovant
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

4YB Stock 12 Month Forecast

Average Price Target

Based on 10 Wall Street analysts offering 12 month price targets for Immunovant in the last 3 months. The average price target is €42.63 with a high forecast of €56.62 and a low forecast of €25.73. The average price target represents a change from the last price of .
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
Highest Price Target€56.62Average Price Target€42.63Lowest Price Target€25.73
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
UBS Analyst forecast on DE:4YB
Unknown Analyst
UBS
Not Ranked
UBS
€20.59€34.31
Hold
Assigned
08/24/26
UBS Remains a Hold on Immunovant (IMVT)
Stifel Nicolaus Analyst forecast on DE:4YB
Stifel Nicolaus
Stifel Nicolaus
€42.03€48.9
Buy
Reiterated
08/11/26
Immunovant (IMVT) Receives a Rating Update from a Top Analyst
H.C. Wainwright Analyst forecast on DE:4YB
H.C. Wainwright
H.C. Wainwright
€34.31€35.17
Buy
Reiterated
08/10/26
Analysts Are Bullish on Top Healthcare Stocks: Corbus Pharmaceuticals (CRBP), Intellia Therapeutics (NTLA)
J.P. Morgan Analyst forecast on DE:4YB
J.P. Morgan
J.P. Morgan
€42.89
Buy
Reiterated
08/10/26
J.P. Morgan Sticks to Their Buy Rating for Immunovant (IMVT)
LifeSci Capital Analyst forecast on DE:4YB
LifeSci Capital
LifeSci Capital
€45.46
Buy
Reiterated
08/07/26
Immunovant Reaffirmed at Buy as IMVT-1402 Trials Advance; $53 Price Target Maintained
Piper Sandler Analyst forecast on DE:4YB
Piper Sandler
Piper Sandler
€56.62
Buy
Reiterated
08/07/26
Piper Sandler Reaffirms Their Buy Rating on Immunovant (IMVT)
Truist Financial Analyst forecast on DE:4YB
Truist Financial
Truist Financial
€25.73
Hold
Reiterated
08/07/26
Truist Financial Keeps Their Hold Rating on Immunovant (IMVT)
Oppenheimer Analyst forecast on DE:4YB
Oppenheimer
Oppenheimer
€46.32
Buy
Reiterated
08/07/26
Immunovant (IMVT) Receives a Buy from Oppenheimer
Bank of America Securities Analyst forecast on DE:4YB
Bank of America Securities
Bank of America Securities
€36.89€38.6
Buy
Reiterated
08/07/26
Bank of America Securities Sticks to Their Buy Rating for Immunovant (IMVT)
Citi
€48.9€52.33
Buy
Reiterated
06/30/26
Immunovant price target raised to $61 from $57 at CitiImmunovant price target raised to $61 from $57 at Citi
Guggenheim Analyst forecast on DE:4YB
Guggenheim
Guggenheim
€37.74€53.18
Buy
Reiterated
05/26/26
Analysts' Top Healthcare Picks: Amneal Pharmaceuticals (AMRX), Immunovant (IMVT)
Wells Fargo Analyst forecast on DE:4YB
Wells Fargo
Wells Fargo
€38.6
Buy
Reiterated
05/21/26
Wells Fargo Sticks to Its Buy Rating for Immunovant (IMVT)
Goldman Sachs Analyst forecast on DE:4YB
Goldman Sachs
Goldman Sachs
€24.88€27.45
Hold
Assigned
04/15/26
Immunovant price target raised to $32 from $29 at Goldman SachsImmunovant price target raised to $32 from $29 at Goldman Sachs
Wolfe Research Analyst forecast on DE:4YB
Wolfe Research
Wolfe Research
€40.32
Buy
Reiterated
04/06/26
Strengthening the Buy Case for IMVT-1402: Targeted Phase 3 Graves’ Disease Strategy and Reproducible Efficacy Support Commercial Potential
Leerink Partners Analyst forecast on DE:4YB
Leerink Partners
Leerink Partners
€44.61€42.89
Buy
Reiterated
04/02/26
Buy Rating Maintained on Immunovant as IMVT-1402 Pipeline Overshadows Batoclimab Setback
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
UBS Analyst forecast on DE:4YB
Unknown Analyst
UBS
Not Ranked
UBS
€20.59€34.31
Hold
Assigned
08/24/26
UBS Remains a Hold on Immunovant (IMVT)
Stifel Nicolaus Analyst forecast on DE:4YB
Stifel Nicolaus
Stifel Nicolaus
€42.03€48.9
Buy
Reiterated
08/11/26
Immunovant (IMVT) Receives a Rating Update from a Top Analyst
H.C. Wainwright Analyst forecast on DE:4YB
H.C. Wainwright
H.C. Wainwright
€34.31€35.17
Buy
Reiterated
08/10/26
Analysts Are Bullish on Top Healthcare Stocks: Corbus Pharmaceuticals (CRBP), Intellia Therapeutics (NTLA)
J.P. Morgan Analyst forecast on DE:4YB
J.P. Morgan
J.P. Morgan
€42.89
Buy
Reiterated
08/10/26
J.P. Morgan Sticks to Their Buy Rating for Immunovant (IMVT)
LifeSci Capital Analyst forecast on DE:4YB
LifeSci Capital
LifeSci Capital
€45.46
Buy
Reiterated
08/07/26
Immunovant Reaffirmed at Buy as IMVT-1402 Trials Advance; $53 Price Target Maintained
Piper Sandler Analyst forecast on DE:4YB
Piper Sandler
Piper Sandler
€56.62
Buy
Reiterated
08/07/26
Piper Sandler Reaffirms Their Buy Rating on Immunovant (IMVT)
Truist Financial Analyst forecast on DE:4YB
Truist Financial
Truist Financial
€25.73
Hold
Reiterated
08/07/26
Truist Financial Keeps Their Hold Rating on Immunovant (IMVT)
Oppenheimer Analyst forecast on DE:4YB
Oppenheimer
Oppenheimer
€46.32
Buy
Reiterated
08/07/26
Immunovant (IMVT) Receives a Buy from Oppenheimer
Bank of America Securities Analyst forecast on DE:4YB
Bank of America Securities
Bank of America Securities
€36.89€38.6
Buy
Reiterated
08/07/26
Bank of America Securities Sticks to Their Buy Rating for Immunovant (IMVT)
Citi
€48.9€52.33
Buy
Reiterated
06/30/26
Immunovant price target raised to $61 from $57 at CitiImmunovant price target raised to $61 from $57 at Citi
Guggenheim Analyst forecast on DE:4YB
Guggenheim
Guggenheim
€37.74€53.18
Buy
Reiterated
05/26/26
Analysts' Top Healthcare Picks: Amneal Pharmaceuticals (AMRX), Immunovant (IMVT)
Wells Fargo Analyst forecast on DE:4YB
Wells Fargo
Wells Fargo
€38.6
Buy
Reiterated
05/21/26
Wells Fargo Sticks to Its Buy Rating for Immunovant (IMVT)
Goldman Sachs Analyst forecast on DE:4YB
Goldman Sachs
Goldman Sachs
€24.88€27.45
Hold
Assigned
04/15/26
Immunovant price target raised to $32 from $29 at Goldman SachsImmunovant price target raised to $32 from $29 at Goldman Sachs
Wolfe Research Analyst forecast on DE:4YB
Wolfe Research
Wolfe Research
€40.32
Buy
Reiterated
04/06/26
Strengthening the Buy Case for IMVT-1402: Targeted Phase 3 Graves’ Disease Strategy and Reproducible Efficacy Support Commercial Potential
Leerink Partners Analyst forecast on DE:4YB
Leerink Partners
Leerink Partners
€44.61€42.89
Buy
Reiterated
04/02/26
Buy Rating Maintained on Immunovant as IMVT-1402 Pipeline Overshadows Batoclimab Setback
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
ODTXOdyssey Therapeutics, Inc.
BTSGBrightSpring Health Services, Inc.
GPCRStructure Therapeutics, Inc. Sponsored ADR
AMLXAmylyx Pharmaceuticals Inc
IMMXImmix Biopharma
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Immunovant

3 Months
Douglas TsaoH.C. Wainwright
Success Rate
11/18 ratings generated profit
61%
Average Return
+7.36%
Copying Douglas Tsao's trades and holding each position for 3 Months would result in 61.11% of your transactions generating a profit, with an average return of +7.36% per trade.
1 Year
Thomas SmithLeerink Partners
Success Rate
12/20 ratings generated profit
60%
Average Return
+73.20%
Copying Thomas Smith's trades and holding each position for 1 Year would result in 60.00% of your transactions generating a profit, with an average return of +73.20% per trade.
2 Years
Thomas SmithLeerink Partners
Success Rate
15/20 ratings generated profit
75%
Average Return
+111.41%
Copying Thomas Smith's trades and holding each position for 2 Years would result in 75.00% of your transactions generating a profit, with an average return of +111.41% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

4YB Analyst Recommendation Trends

Rating
Apr 26
May 26
Jun 26
Jul 26
Aug 26
Strong Buy
12
10
11
3
2
Buy
4
7
7
8
8
Hold
3
3
2
1
2
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
19
20
20
12
12
In the current month, 4YB has received 10 Buy Ratings, 2 Hold Ratings, and 0 Sell Ratings. 4YB average Analyst price target in the past 3 months is 42.63.
Each month's total comprises the sum of three months' worth of ratings.

4YB Financial Forecast

4YB Earnings Forecast

Next quarter’s earnings estimate for 4YB is -€0.63 with a range of -€0.68 to -€0.54. The previous quarter’s EPS was -€0.64. 4YB beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 4YB has Performed in-line its overall industry.
Next quarter’s earnings estimate for 4YB is -€0.63 with a range of -€0.68 to -€0.54. The previous quarter’s EPS was -€0.64. 4YB beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 4YB has Performed in-line its overall industry.
No data currently available

4YB Sales Forecast

Next quarter’s sales forecast for 4YB is €0.00 with a range of €0.00 to €0.00. The previous quarter’s sales results were €0.00. 4YB beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 4YB has Performed in-line its overall industry.
Next quarter’s sales forecast for 4YB is €0.00 with a range of €0.00 to €0.00. The previous quarter’s sales results were €0.00. 4YB beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 4YB has Performed in-line its overall industry.

4YB Stock Forecast FAQ

What is DE:4YB’s average 12-month price target, according to analysts?
Based on analyst ratings, Immunovant’s 12-month average price target is 42.63.
    What is DE:4YB’s upside potential, based on the analysts’ average price target?
    Currently there's no upside potential for DE:4YB, based on the analysts’ average price target.
    Can I see which stocks the top-ranking analysts are rating?
    Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
      How can I follow the stock ratings of top Wall Street analysts?
      Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
        Is Immunovant a Buy, Sell or Hold?
        Immunovant has a consensus rating of Strong Buy, which is based on 8 buy ratings, 2 hold ratings and 0 sell ratings.
          What is Immunovant’s share price target?
          The average share price target for Immunovant is 42.63. This is based on 10 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
          The highest analyst share price target is €56.62 ,and the lowest forecast is €25.73. The average share price target represents N/A Increase from the current price of N/A.
            What do analysts say about Immunovant?
            Immunovant’s analyst rating consensus is a Strong Buy. This is based on the ratings of 10 Wall Streets Analysts.
              How can I buy shares of Immunovant?
              To buy shares of DE:4YB, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.